Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts

Eli Lilly (LLY) shares underperformed the broader market in recent trading, closing down 1.44% while the S&P 500 gained 0.94%. The company's upcoming earnings release on August 7, 2025, is expected to show a 41.84% EPS increase to $5.56 and a 28.02% revenue increase to $14.47 billion compared to the same quarter last year. Despite strong projected full-year growth of 68.98% in EPS and 33.03% in revenue, the stock currently holds a Zacks Rank of #3 (Hold) and trades at a premium Forward P/E of 37.33 compared to its industry average of 13.93.

Analysis

Eli Lilly (LLY) recently underperformed the broader market, closing at $807.58 with a -1.44% change while the S&P 500 gained 0.94%. Despite this single-day dip, the drugmaker's shares have appreciated 8.18% over the past month, outpacing both the Medical sector's 4.95% gain and the S&P 500's 1.67% rise. Market attention is now focused on the upcoming earnings release scheduled for August 7, 2025, where Eli Lilly is anticipated to report a significant 41.84% year-over-year increase in EPS to $5.56, and a 28.02% rise in revenue to $14.47 billion for the quarter. Full-year Zacks Consensus Estimates project even more substantial growth, with EPS expected to surge by 68.98% to $21.95 and revenue by 33.03% to $59.92 billion compared to the previous year. However, the Zacks Consensus EPS estimate has seen a slight downward revision of 0.61% in the past month, and the stock currently holds a Zacks Rank of #3 (Hold). From a valuation perspective, LLY trades at a Forward P/E ratio of 37.33, a notable premium to its industry's average of 13.93. Its PEG ratio of 1.2 is, however, in line with the Large Cap Pharmaceuticals industry average of 1.27. The industry itself is favorably positioned, ranking in the top 15% of over 250 industries tracked by Zacks.

Key Decisions for Investors

• Investors should monitor Eli Lilly's upcoming earnings on August 7, 2025, for confirmation of the strong projected growth, as this will be critical given the stock's premium valuation.
• The recent slight downward revision in EPS estimates and the Zacks Rank #3 (Hold) suggest a cautious approach; significant deviations from expected earnings or guidance could impact the stock considerably.
• While the long-term growth outlook appears robust, the current Forward P/E of 37.33 warrants careful consideration of risk-reward, especially when compared to industry peers, despite a PEG ratio that aligns with the sector.